FDA-APPROVED FOR A SPECIFIC USE
What is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for the specific treatment of excess abdominal fat in HIV patients with lipodystrophy, and is studied more broadly for its effects on growth hormone signaling.
Areas of Research Interest
- Growth hormone secretion pathway studies
- Body composition and visceral fat research
- Cognitive function studies in aging populations
- Metabolic health research
Regulatory Status
Tesamorelin is FDA-approved under the brand name Egrifta specifically for reducing excess abdominal fat in HIV-associated lipodystrophy. Uses outside of this approved indication are considered off-label and are not FDA-approved.
Educational information only. This content is not intended to diagnose, treat, cure, or prevent any disease, and does not provide guidance on personal use, dosing, or administration. Consult qualified professionals and current regulatory sources for guidance specific to your situation.